Acadia Pharmaceuticals (ACAD) Change in Accured Expenses (2010 - 2026)

Acadia Pharmaceuticals' Change in Accured Expenses history runs 17 years deep, the most recent figure standing at $23.6 million for Q1 2026.

• On a quarterly basis, Change in Accured Expenses rose 1135.29% year-over-year to $23.6 million in Q1 2026; TTM through Mar 2026 was $2.4 million, a 72.55% decrease from a year earlier, with the FY2025 full-year figure at -$19.3 million, down 762.26% from the prior year.
• Change in Accured Expenses improved to $23.6 million in Q1 2026 per ACAD's latest filing, from -$15.1 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $89.6 million in Q4 2023 and bottomed at -$37.4 million in Q4 2024.
• The 5-year median for Change in Accured Expenses is $1.1 million (2024), against an average of $6.0 million.
• Biggest YoY gain for Change in Accured Expenses was 3334.97% in 2023; the steepest drop was 2625.92% in 2023.
• Year by year, Change in Accured Expenses stood at $2.6 million in 2022, then soared by 3334.97% to $89.6 million in 2023, then plunged by 141.72% to -$37.4 million in 2024, then jumped by 59.61% to -$15.1 million in 2025, then soared by 256.03% to $23.6 million in 2026.
• Per Business Quant, the three latest ACAD Change in Accured Expenses figures stand at $23.6 million (Q1 2026), -$15.1 million (Q4 2025), and -$25.5 million (Q3 2025).